SCHEMBL937818

SCHEMBL937818

CNC(=O)c1cc(Oc2cccc(N(C=O)Nc3cc(C(C)(C)C)no3)c2)ccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.45
RAF1 P04049 7/20 0.45
BRAF P15056 11/20 0.43
ABL1 P00519 2/20 0.41
RET P07949 2/20 0.41
MAPK14 Q16539 3/20 0.40
LCK P06239 2/20 0.40
FYN P06241 2/20 0.40
MAPK13 O15264 2/20 0.40
PLK4 O00444 1/20 0.40
AURKA O14965 1/20 0.40
JAK2 O60674 1/20 0.40
MAP4K4 O95819 1/20 0.40
LYN P07948 1/20 0.40
ROS1 P08922 1/20 0.40
SRC P12931 1/20 0.40
RPS6KB1 P23443 1/20 0.40
EPHA2 P29317 1/20 0.40
TYK2 P29597 1/20 0.40
AXL P30530 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL937005 0.86 RAF1 (0.60) KDRRAF1BRAFABL1RET
SCHEMBL937919 0.85 ALDH1A1 (0.38) KDRRAF1BRAFMAPK14MAPK13
SCHEMBL937748 0.79 RAF1 (0.37) RAF1BRAFMAPK14MAPK13LYN
SCHEMBL938508 0.75 RET (0.69) KDRRAF1BRAFABL1RET
SCHEMBL939153 0.75 RAF1 (0.63) KDRRAF1BRAFABL1RET
SCHEMBL5426692 0.73 KDR (0.51) KDRRAF1BRAFABL1MAPK14
SCHEMBL3542762 0.72 RAF1 (0.58) KDRRAF1BRAFABL1RET
SCHEMBL3475376 0.72 RAF1 (0.64) KDRRAF1ABL1RETMAPK14
SCHEMBL939889 0.71 RAF1 (0.61) KDRRAF1BRAFMAPK14MAPK13
SCHEMBL937135 0.71 RAF1 (0.37) RAF1BRAFMAPK14MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2324825-A1 Aryl ureas with angiogenesis inhibiting activity Bayer Healthcare LLC (US) 2011-05-25 EP claimed
US-10653684-B2 Aryl ureas with angiogenisis inhibiting activity BAYER HEALTHCARE LLC (US) 2020-05-19 US disclosed
US-20180296541-A9 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2018-10-18 US disclosed
US-20160015697-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2016-01-21 US disclosed
US-8618141-B2 Aryl ureas with angiogenesis inhibiting activity BAYER HEALTHCARE LLC (US) 2013-12-31 US disclosed
US-20120289552-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2012-11-15 US disclosed
US-8242147-B2 Aryl ureas with angiogenisis inhibiting activity BAYER HEALTHCARE LLC (US) 2012-08-14 US disclosed
US-20110015195-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY DUMAS JACQUES 2011-01-20 US disclosed
US-7838541-B2 Aryl ureas with angiogenesis inhibiting activity BAYER HEALTHCARE, LLC (US) 2010-11-23 US disclosed
US-20080227828-A1 Aryl Ureas With Angiogenisis Inhibiting Activity BAYER HEALTHCARE LLC 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180296541-A9 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY FLT1, FLT4, KDR KDR 3/4885RAF1 867/4885BRAF 487/4885
US-10653684-B2 Aryl ureas with angiogenisis inhibiting activity FLT1, FLT4, KDR KDR 3/4885RAF1 867/4885BRAF 487/4885
US-20110015195-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY FLT1, FLT4, KDR KDR 3/4885RAF1 867/4885BRAF 487/4885
US-20080227828-A1 Aryl Ureas With Angiogenisis Inhibiting Activity FLT1, FLT4, KDR KDR 3/4885RAF1 867/4885BRAF 487/4885
US-20120289552-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY FLT4, FLT1, KDR KDR 3/4885RAF1 817/4885BRAF 290/4885
US-20160015697-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY FLT1, FLT4, KDR KDR 3/4885RAF1 867/4885BRAF 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.